

Dear David,

On behalf of the ADEPT committee, thank you very much for submitting your protocol "*The comparative effectiveness across severe asthma biologic classes (Anti-IL5 versus Anti-IgE) in patients eligible for both therapies*". Please see below reference details for your application.

<i>Date of Application</i>	09/07/2020
<i>Date of Approval</i>	27/07/2020
<i>Approval Type</i>	Chair approval
<i>Title of Research Database</i>	ISAR
<i>Title of Protocol</i>	<i>The comparative effectiveness across severe asthma biologic classes (Anti-IL5 versus Anti-IgE) in patients eligible for both therapies</i>
<i>ADEPT Protocol Reference</i>	PROTOCOL2279
<i>ADEPT Approval Reference</i>	ADEPT0920
<i>Lead Investigator & Contact details</i>	Prof. David Price dprice@opri.sg

On behalf of the ADEPT committee, I am pleased to **approve** your protocol named above.

We wish you all the best with this and any future work undertaken by you and your organisation.

Yours Sincerely



Dr Todor Popov (ADEPT Chair)